 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
 |
 |
 |
 |
 |
|
||||||
|
Research Use Only Products Lp (a) (Lipoprotein (a)): an independent risk factor for Coronary Artery Disease which has the best correlation with the internationally recognized reference method.2 RLP-C® (Remnant Lipoprotein Cholesterol): produced from VLDL and chylomicrons by the action of LPL; also an indicator for the assessment of CHD risk, especially in patients with normal cholesterol and LDL.3 Apo A-I (Apolipoprotein A-I): aids in identifying individuals with genetic disorders that lead to low HDL levels. Apo B (Apolipoprotein B): plays an essential role in the delivery of cholesterol to the tissues; an independent CHD risk factor, especially when LDL is normal. Apo A II* (Apolipoprotein A II): activates LCAT as an aid in the removal of free cholesterol from extra hepatic tissues. 1 Apo CII* (Apolipoprotein CII): normally promotes HDL production, aids in the differential diagnosis of Type I dyslipidemia due to LPL deficiency. There is a four-fold increase observed in Type III dyslipidemia.1 Apo CIII* (Apolipoprotein CIII): increased levels inhibit triglyceride hydrolysis and disrupts HDL particle maturation. Apo E* (Apolipoprotein E): aid to characterizing Type III dyslipidemia. Its presence increases the concentration of both total cholesterol and LDL. It is related to increased risk of CHD.1 Pre Beta I HDL*: the first product of lipidation of APO (AI) and likely acceptor of cholesterol. NEFA (Non-esterified Fatty Acids): fundamental units in the structure of lipids in membranes and lipoproteins. NEFA forms cholesterol esters which compromise the core of LDL and VLDL. Increases in NEFA are related to premature CAD and are seen in patients with Type 2 Diabetes, obesity, and elevated triglycerides.1 CETP* (Cholesteryl Ester Transfer Protein): risk factor associated with atherosclerosis and a diagnostic indicator of success of statin therapy. LCAT* (Lecithin cholesterol Acyltransferase): deficiency will lead to decreased HDL levels and is a predictor of HDL particle size and CHD.1 LPL* (Lipoprotein Lipase): an essential factor for HDL maturation process which regulates HDL concentration; low levels are associated with CHD. Oxidized LDL*: oxidation of LDL is a key step in in the deposition of cholesterol in the arterial intima. Apo (B48)*: distributed in Triglyceride rich lipoprotein remnants of intestinal origin. *Research Use Only 1. Rifai et al, Handbook of
Lipoprotein Testing, 2nd Edition, AACC Press, 2000.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
